B6 mice infected with LP-BM5 develop severe immunodeficiency (termed murine acquired immunodeficiency syndrome (MAIDS)) and peripheral neuropathy. To determine whether microglial CD40 is involved in LP-BM5-induced peripheral neuropathy, B6-CD40 knockout (KO) mice and B6-CD40 KO mice adoptively transferred either total leukocytes or B cells were examined for behavioral sensitivity, tissue viral loads, cytokine responses, and the development of MAIDS. All three CD40 KO groups developed MAIDS, the severity of which was correlated with peripheral cytokine responses. CD40 KO mice displayed significantly reduced mechanical hypersensitivity post-infection compared to wild-type mice regardless of cell transfer. These findings support microglial CD40 involvement in LP-BM5-induced peripheral neuropathy.
Introduction
Human immunodeficiency virus (HIV)-associated peripheral neuropathy is the most common neurological complication associated with HIV infection, and distal symmetrical polyneuropathy (DSP) is the most common form of HIV-associated peripheral neuropathy. It is estimated that about one out of three HIV/acquired immunodeficiency syndrome (AIDS) patients experience DSP (So et al., 1988; Pettersen et al., 2006) . Despite the extensive study of HIV infection, HIV-associated neuropathy is an under-studied area, in part due to the lack of an appropriate animal model. Currently, there are no US FDA-approved pharmacological agents specifically designed for the treatment of HIV-associated neuropathy (Verma et al., 2005) .
LP-BM5 is a retroviral mixture that contains mainly a pathogenic yet replication-defective virus (BM5def) and a non-pathogenic helper virus (ecotropic (mouse tropic) virus (BM5eco)) (Chattopadhyay et al., 1989) . LP-BM5 infection in susceptible C57BL/6 (B6) mice induces a HIV-like immunodeficiency syndrome, termed murine AIDS (MAIDS). Following LP-BM5 infection, B6 mice experience splenomegaly, lymphadenopathy, polyclonal hypergammaglobulinemia, profoundly decreased T and B cell responses to mitogens, increased susceptibility to opportunistic pathogens, and the development of terminal B cell lymphomas (Jolicoeur, 1991) . The mechanisms of viral pathogenesis in MAIDS have been extensively studied. Significantly, it has been found that both CD4 + T lymphocytes and B lymphocytes and the CD154 (CD40L)-CD40 interaction between these two cell populations are necessary for MAIDS induction and progression (Green et al., 1996; Simard et al., 1997; Green et al., 1998 Green et al., , 2001 . Specifically, the CD4 + T-B cell interaction during the early phase following infection is thought to be critical in the development of MAIDS, as blocking the CD40L-CD40 interaction beginning at 3-4 weeks post-infection (p.i.) lead to a significant reduction in MAIDS severity in about 60% of infected mice (Green et al., 1998) . Recently, we demonstrated that B6 mice infected with LP-BM5 displayed both behavioral and pathological signs of peripheral neuropathy along with tissue-specific cytokine responses. Further, these changes could be reduced or reversed by the anti-retroviral agent zidovudine (AZT) (Cao et al., 2012 ). In the current study, to determine whether spinal cord microglial CD40 signaling is involved in LP-BM5-induced peripheral neuropathy, B6-CD40 knockout (KO) mice were adoptively transferred either total leukocytes or B cells to establish LP-BM5-induced immune deficiency, and LP-BM5-induced sensory hypersensitivity, a behavioral sign of peripheral neuropathy, was then examined. Our data support a contributing role of microglial CD40 in the development of sensory hypersensitivity following LP-BM5 infection and suggest that the lumbar spinal cord viral load and the subsequent cytokine responses are involved in the microglial CD40-mediated peripheral neuropathy following LP-BM5 infection.
Materials and methods

Mice
B6 mice and B6-CD40 KO mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and male adult mice (8-9 wks old) were used in all experiments. All mice were allowed to habituate to the institutional animal facility for at least one week before experimental use. All mice were group-housed (four per cage) with food and water ad libitum and maintained on a 12-h light/dark cycle. The Journal of Neuroimmunology 261 (2013) 37-43 
